Vaccination of Transplant Recipients

Chapter

Abstract

Infections have been major obstacles for successful transplantations. Thus, infection prevention is very important. Immunizations can protect the recipient against serious infections that may occur during the early or late post-transplant period. Despite that several sets of recommendations have been published during the last decade, the uptake of these recommendations is variable among physicians dealing with transplant patients. Furthermore, transplant techniques evolve and recommendations and practices have to be adapted accordingly. This chapter reviews current information and recommendations regarding vaccinations of hematopoietic stem cell and solid organ transplant recipients.

Keywords

Immunizations Stem cell transplantation Solid organ transplantation influenza Pneumococci Varicella-zoster virus Measles 

References

  1. 1.
    Lum L. The kinetics of immune reconstitution after human marrow transplantation. Blood. 1987;69:369–80.PubMedGoogle Scholar
  2. 2.
    Lum L, Seigneuret M, Storb R. The transfer of antigen-specific humoral immunity from marrow donors to marrow recipients. J Clin Immunol. 1986;6(5):389–96.PubMedCrossRefGoogle Scholar
  3. 3.
    Lum L, Noges J, Beatty P, Martin P, Deeg J, Doney K, et al. Transfer of specific immunity in marrow recipients given HLA-mismatched, T cell-depleted, or HLA-identical marrow grafts. Bone Marrow Transplant. 1988;3(5):399–406.PubMedGoogle Scholar
  4. 4.
    Lum L, Munn N, Schanfield M, Storb R. The detection of specific antibody formation to recall antigens after human bone marrow transplantation. Blood. 1986;67(3):582–7.PubMedGoogle Scholar
  5. 5.
    Saxon A, Mitsuyaso R, Stevens R, Champlin R, Kimata H, Gale R. Transfer of specific immune responses after bone marrow transplantation. J Clin Invest. 1986;78:959–67.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Wahren B, Gahrton G, Linde A, Ljungman P, Lönnqvist B, Ringdén O, et al. Transfer and persistence of viral antibody-producing cells in bone marrow transplantation. J Infect Dis. 1984;150:358–65.PubMedCrossRefGoogle Scholar
  7. 7.
    Witherspoon R, Storb R, Ochs H, Flournoy N, et al. Recovery of antibody production in human allogeneic marrow graft recipients: influence of time posttransplantation, the presence or absence of chronic graft-versus -host disease, and antithymocyte globulin treatment. Blood. 1981;58:360–8.PubMedGoogle Scholar
  8. 8.
    Witherspoon R, Matthews D, Storb R, Atkinson K, Cheever M, Deeg H, et al. Recovery of in vivo cellular immunity after human marrow grafting. Influence of time postgrafting and acute graft-versus-host disease. Transplantation. 1984;37:145–50.PubMedCrossRefGoogle Scholar
  9. 9.
    Wimperis J, Brenner M, Prentice H, Reittie J, Karayiannis P, Griffiths P, et al. Transfer of a functioning humoral immune system in transplantation of T-lymphocyte-depleted bone marrow. Lancet. 1986;1:339–43.PubMedCrossRefGoogle Scholar
  10. 10.
    Molrine D, Antin J, Guinan E, Soiffer R, Ambrosino D, Maldonado J, et al., editors. Pneumococcal conjugate vaccine (PCV) elicits protective responses in allogeneic bone marrow transplant (BMT) recipients. Chicago: ICAAC; 2001.Google Scholar
  11. 11.
    Molrine D, Guinan E, Antin J, Parsons S, Weinstein H, Wheeler C, et al. Donor immunization with Haemophilus influenzae type B (HIB)-conjugate vaccine in allogeneic bone marrow transplantation. Blood. 1996;87:3012–8.PubMedGoogle Scholar
  12. 12.
    Ilan Y, Nagler A, Adler R, Naparstek E, Or R, Slavin S, et al. Adoptive transfer of immunity to hepatitis B virus after T cell-depleted allogeneic bone marrow transplantation. Hepatology. 1993;18(2):246–52.PubMedGoogle Scholar
  13. 13.
    Brugger S, Oesterreicher C, Hofmann H, Kalhs P, Greinix H, Müller C. Hepatitis B virus clearance by transplantation of bone marrow from hepatitis B immunized donor. Lancet. 1997;349(9057):996–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Ilan Y, Nagler A, Adler R, Tur Kaspa R, Slavin S, Shouval D. Ablation of persistent hepatitis B by bone marrow transplantation from a hepatitis B-immune donor. Gastroenterology. 1993;104(6):1818–21.PubMedCrossRefGoogle Scholar
  15. 15.
    Ambati A, Boas LS, Ljungman P, Testa L, de Oliveira JF, Aoun M, et al. Evaluation of pretransplant influenza vaccination in hematopoietic SCT: a randomized prospective study. Bone Marrow Transplant. 2015. Epub 2015/03/24.Google Scholar
  16. 16.
    Ljungman P, Lewensohn-Fuchs I, Hammarstrom V, Aschan J, Brandt L, Bolme P, et al. Long-term immunity to measles, mumps, and rubella after allogeneic bone marrow transplantation. Blood. 1994;84(2):657–63.PubMedGoogle Scholar
  17. 17.
    Ljungman P, Wiklund HM, Duraj V, Hammarström L, Lönnqvist B, Paulin T, et al. Response to tetanus toxoid immunization after allogeneic bone marrow transplantation. J Infect Dis. 1990;162(2):496–500.PubMedCrossRefGoogle Scholar
  18. 18.
    Ljungman P, Duraj V, Magnius L. Response to immunization against polio after allogeneic marrow transplantation. Bone Marrow Transplant. 1991;7(2):89–93.PubMedGoogle Scholar
  19. 19.
    Engelhard D, Handsher R, Naparstek E, Hardan I, Strauss N, Aker M, et al. Immune responses to polio vaccination in bone marrow transplant recipients. Bone Marrow Transplant. 1991;8:295–300.PubMedGoogle Scholar
  20. 20.
    Parkkali T, Stenvik M, Ruutu T, Hovi T, Volin L, Ruutu P. Randomized comparison of early and late vaccination with inactivated poliovirus vaccine after allogeneic BMT. Bone Marrow Transplant. 1997;20:663–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Machado CM, Goncalves FB, Pannuti CS, Dulley FL, de Souza VA. Measles in bone marrow transplant recipients during an outbreak in Sao Paulo, Brazil. Blood. 2002;99(1):83–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Horwitz SM, Negrin RS, Blume KG, Breslin S, Stuart MJ, Stockerl-Goldstein KE, et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood. 2004;103(3):777–83.PubMedCrossRefGoogle Scholar
  23. 23.
    Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):e44–100. Epub 2013/12/07.PubMedCrossRefGoogle Scholar
  24. 24.
    Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):309–18. Epub 2014/01/15.PubMedCrossRefGoogle Scholar
  25. 25.
    Harris AE, Styczynski J, Bodge M, Mohty M, Savani BN, Ljungman P. Pretransplant vaccinations in allogeneic stem cell transplantation donors and recipients: an often-missed opportunity for immunoprotection? Bone Marrow Transplant. 2015;50:899–903.PubMedCrossRefGoogle Scholar
  26. 26.
    Aschan J, Ringdén O, Ljungman P, Andersson J, Lewensohn FI, Forsgren M. Influenza B in transplant patients. Scand J Infect Dis. 1989;21(3):349–50.PubMedCrossRefGoogle Scholar
  27. 27.
    Ljungman P, Andersson J, Aschan J, Barkholt L, Ehrnst A, Johansson M, et al. Influenza A in immunocompromised patients. Clin Infect Dis. 1993;17(2):244–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Ljungman P, Ward KN, Crooks BN, Parker A, Martino R, Shaw PJ, et al. Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2001;28(5):479–84.PubMedCrossRefGoogle Scholar
  29. 29.
    Whimbey E, Elting LS, Couch RB, Lo W, Williams L, Champlin RE, et al. Influenza A virus infections among hospitalized adult bone marrow transplant recipients. Bone Marrow Transplant. 1994;13(4):437–40.PubMedGoogle Scholar
  30. 30.
    Machado CM, Cardoso MR, da Rocha IF, Boas LS, Dulley FL, Pannuti CS. The benefit of influenza vaccination after bone marrow transplantation. Bone Marrow Transplant. 2005;36(10):897–900.PubMedCrossRefGoogle Scholar
  31. 31.
    Engelhard D, Zakay-Rones Z, Shapira MY, Resnick I, Averbuch D, Grisariu S, et al. The humoral immune response of hematopoietic stem cell transplantation recipients to AS03-adjuvanted A/California/7/2009 (H1N1)v-like virus vaccine during the 2009 pandemic. Vaccine. 2011;29(9):1777–82. Epub 2011/01/11.PubMedCrossRefGoogle Scholar
  32. 32.
    Pauksen K, Linde A, Hammarstrom V, Sjolin J, Carneskog J, Jonsson G, et al. Granulocyte-macrophage colony-stimulating factor as immunomodulating factor together with influenza vaccination in stem cell transplant patients. Clin Infect Dis. 2000;30(2):342–8. Epub 2000/02/15.PubMedCrossRefGoogle Scholar
  33. 33.
    de Lavallade H, Garland P, Sekine T, Hoschler K, Marin D, Stringaris K, et al. Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host. Haematologica. 2011;96(2):307–14. Epub 2010/10/26.PubMedCrossRefGoogle Scholar
  34. 34.
    Engelhard D, Nagler A, Hardan I, Morag A, Aker M, Baciu H, et al. Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients. Bone Marrow Transplant. 1993;11(1):1–5.PubMedGoogle Scholar
  35. 35.
    Issa NC, Marty FM, Gagne LS, Koo S, Verrill KA, Alyea EP, et al. Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2011;17(3):434–8. Epub 2010/10/19.PubMedCrossRefGoogle Scholar
  36. 36.
    Dhedin N, Krivine A, Le Corre N, Mallet A, Lioure B, Bay JO, et al. Comparable humoral response after two doses of adjuvanted influenza A/H1N1pdm2009 vaccine or natural infection in allogeneic stem cell transplant recipients. Vaccine. 2014;32(5):585–91. Epub 2013/12/18.PubMedCrossRefGoogle Scholar
  37. 37.
    Gueller S, Allwinn R, Mousset S, Martin H, Wieters I, Herrmann E, et al. Enhanced immune response after a second dose of an AS03-adjuvanted H1N1 influenza A vaccine in patients after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17(10):1546–50. Epub 2011/02/18.PubMedCrossRefGoogle Scholar
  38. 38.
    Avetisyan G, Aschan J, Hassan M, Ljungman P. Evaluation of immune responses to seasonal influenza vaccination in healthy volunteers and in patients after stem cell transplantation. Transplantation. 2008;86(2):257–63.PubMedCrossRefGoogle Scholar
  39. 39.
    Ambati A, Einarsdottir S, Magalhaes I, Poiret T, Bodenstein R, LeBlanc K, et al. Immunogenicity of virosomal adjuvanted trivalent influenza vaccination in allogeneic stem cell transplant recipients. Transpl Infect Dis. 2015;17:371–9. Epub 2015/03/31.PubMedCrossRefGoogle Scholar
  40. 40.
    Ljungman P, Cordonnier C, Einsele H, Englund J, Machado CM, Storek J, et al. HCT recipient vaccinations. Bone Marrow Transplant. 2009;44(8):521–6.PubMedCrossRefGoogle Scholar
  41. 41.
    Locasciulli A, Alberti A, Bandini G, Polchi P, Arcese W, Alessandrino P, et al. Allogeneic bone marrow transplantation from HBsAg + donors: a multicenter study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood. 1995;86(8):3236–40.PubMedGoogle Scholar
  42. 42.
    Ilan Y, Nagler A, Zeira E, Adler R, Slavin S, Shouval D. Maintenance of immune memory to the hepatitis B envelope protein following adoptive transfer of immunity in bone marrow transplant recipients. Bone Marrow Transplant. 2000;26(6):633–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Onozawa M, Hashino S, Darmanin S, Okada K, Morita R, Takahata M, et al. HB vaccination in the prevention of viral reactivation in allogeneic hematopoietic stem cell transplantation recipients with previous HBV infection. Biol Blood Marrow Transplant. 2008;14(11):1226–30. Epub 2008/10/23.PubMedCrossRefGoogle Scholar
  44. 44.
    Takahata M, Hashino S, Onozawa M, Shigematsu A, Sugita J, Fujimoto K, et al. Hepatitis B virus (HBV) reverse seroconversion (RS) can be prevented even in non-responders to hepatitis B vaccine after allogeneic stem cell transplantation: long-term analysis of intervention in RS with vaccine for patients with previous HBV infection. Transpl Infect Dis. 2014;16(5):797–801. Epub 2014/08/27.PubMedCrossRefGoogle Scholar
  45. 45.
    CDC. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. MMWR Morb Mortal Wkly Rep. 2000;49(RR-10):1–125.Google Scholar
  46. 46.
    Engelhard D, Cordonnier C, Shaw PJ, Parkalli T, Guenther C, Martino R, et al. Early and late invasive pneumococcal infection following stem cell transplantation: a European Bone Marrow Transplantation survey. Br J Haematol. 2002;117(2):444–50.PubMedCrossRefGoogle Scholar
  47. 47.
    Cordonnier C, Bernaudin JF, Bierling P, Huet Y, Vernant JP. Pulmonary complications occurring after allogeneic bone marrow transplantation. A study of 130 consecutive transplanted patients. Cancer. 1986;58(5):1047–54.PubMedCrossRefGoogle Scholar
  48. 48.
    Aucouturier P, Barra A, Intrator L, Cordonnier C, Schulz D, Duarte F, et al. Long lasting IgG subclass and antibacterial polysaccharide antibody deficiency after allogeneic bone marrow transplantation. Blood. 1987;70(3):779–85.PubMedGoogle Scholar
  49. 49.
    Winston DJ, Schiffman G, Wang DC, Feig SA, Lin CH, Marso EL, et al. Pneumococcal infections after human bone-marrow transplantation. Ann Intern Med. 1979;91(6):835–41.PubMedCrossRefGoogle Scholar
  50. 50.
    Guinan EC, Molrine DC, Antin JH, Lee MC, Weinstein HJ, Sallan SE, et al. Polysaccharide conjugate vaccine responses in bone marrow transplant patients. Transplantation. 1994;57(5):677–84.PubMedCrossRefGoogle Scholar
  51. 51.
    Parkkali T, Kayhty H, Ruutu T, Volin L, Eskola J, Ruutu P. A comparison of early and late vaccination with Haemophilus influenzae type B conjugate and pneumococcal polysaccharide vaccines after allogeneic BMT. Bone Marrow Transplant. 1996;18:961–7.PubMedGoogle Scholar
  52. 52.
    Avanzini M, Carra A, Macccario R, Zecca M, Pignatti P, Marconi M, et al. Antibody response to pneumococcal vaccine in children receiving bone marrow transplantation. J Clin Immunol. 1995;15:137–44.PubMedCrossRefGoogle Scholar
  53. 53.
    Barra A, Cordonnier C, Preziosi MP, Intrator L, Hessel L, Fritzell B, et al. Immunogenicity of Haemophilus influenzae type b conjugate vaccine in allogeneic bone marrow recipients. J Infect Dis. 1992;166(5):1021–8.PubMedCrossRefGoogle Scholar
  54. 54.
    Hammarström V, Pauksen K, Azinge J, Öberg G, Ljungman P. The influence of graft versus host reaction on the response to pneumococcal vaccination in bone marrow transplant patients. Support Care Cancer. 1993;1:195–9.PubMedCrossRefGoogle Scholar
  55. 55.
    Lortan J, Vellodi A, Jurges E, Hugh-Jones K. Class- and subclass-specific pneumococcal antibody levels and response to immunization after bone marrow transplantation. Clin Exp Immunol. 1992;88:512–9.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Spoulou V, Victoratos P, Ioannidis JP, Grafakos S. Kinetics of antibody concentration and avidity for the assessment of immune response to pneumococcal vaccine among children with bone marrow transplants. J Infect Dis. 2000;182(3):965–9.PubMedCrossRefGoogle Scholar
  57. 57.
    Parkkali T, Kayhty H, Anttila M, Ruutu T, Wuorimaa T, Soininen A, et al. IgG subclasses and avidity of antibodies to polysaccharide antigens in allogeneic BMT recipients after vaccination with pneumococcal polysaccharide and Haemophilus influenzae type b conjugate vaccines. Bone Marrow Transplant. 1999;24(6):671–8.PubMedCrossRefGoogle Scholar
  58. 58.
    Parkkali T, Vakevainen M, Kayhty H, Ruutu T, Ruutu P. Opsonophagocytic activity against Streptococcus pneumoniae type 19F in allogeneic BMT recipients before and after vaccination with pneumococcal polysaccharide vaccine. Bone Marrow Transplant. 2001;27(2):207–11.PubMedCrossRefGoogle Scholar
  59. 59.
    Cordonnier C, Labopin M, Chesnel V, Ribaud P, De La Camara R, Martino R, et al. Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation. Clin Infect Dis. 2009;48(10):1392–401. Epub 2009/04/17.PubMedCrossRefGoogle Scholar
  60. 60.
    Kumar D, Chen MH, Welsh B, Siegal D, Cobos I, Messner HA, et al. A randomized, double blind trial of pneumococcal vaccination in adult allogeneic stem cell transplant donors and recipients. Clin Infect Dis. 2007;45.Google Scholar
  61. 61.
    Meisel R, Kuypers L, Dirksen U, Schubert R, Gruhn B, Strauss G, et al. Pneumococcal conjugate vaccine provides early protective antibody responses in children after related and unrelated allogeneic stem cell transplantation. Blood. 2007;109:2322–6.PubMedCrossRefGoogle Scholar
  62. 62.
    Cordonnier C, Ljungman P, Juergens C, Maertens J, Selleslag D, Sundaraiyer V, et al. Immunogenicity, safety, and tolerability of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in recipients of allogeneic hematopoietic stem cell transplant aged 2 years and older: an open-label study. Clin Infect Dis. 2015. Epub 2015/04/15.Google Scholar
  63. 63.
    Cordonnier C, Labopin M, Robin C, Ribaud P, Cabanne L, Chadelat C, et al. Long-term persistence of the immune response to antipneumococcal vaccines after Allo-SCT: 10-year follow-up of the EBMT-IDWP01 trial. Bone Marrow Transplant. 2015;50:978–83. Epub 2015/04/14.PubMedCrossRefGoogle Scholar
  64. 64.
    Avanzini MA, Carra AM, Maccario R, Zecca M, Zecca G, Pession A, et al. Immunization with Haemophilus influenzae type b conjugate vaccine in children given bone marrow transplantation: comparison with healthy age-matched controls. J Clin Immunol. 1998;18(3):193–201.PubMedCrossRefGoogle Scholar
  65. 65.
    Ljungman P. Immunization of transplant recipients. Bone Marrow Transplant. 1999;23(7):635–6.PubMedCrossRefGoogle Scholar
  66. 66.
    Ljungman P, Cordonnier C, de Bock R, Einsele H, Engelhard D, Grundy J, et al. Immunisations after bone marrow transplantation: results of a European survey and recommendations from the infectious diseases working party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1995;15(3):455–60.PubMedGoogle Scholar
  67. 67.
    Parkkali T, Ölander R-M, Ruutu T, Vuontela K, Volin L, Eskola J, et al. A randomized comparison between early and late vaccination with tetanus toxoid vaccine after allogeneic BMT. Bone Marrow Transplant. 1997;19:933–8.PubMedCrossRefGoogle Scholar
  68. 68.
    Gerritsen E, Van Tol M, Van’t Veer M, Wels J, Khouw I, Touw C, et al. Clonal dysregulation of the antibody response to tetanus-toxoid after bone marrow transplantation. Blood. 1994;84:4374–82.PubMedGoogle Scholar
  69. 69.
    Florax A, Ehlert K, Becker K, Vormoor J, Groll A. Bordetella pertussis respiratory infection following hematpoietic stem cell transplantation: time for universal vaccination? Bone Marrow Transplant. 2006;38:639–40.PubMedCrossRefGoogle Scholar
  70. 70.
    Kochethu G, Clark F, Craddock C. Pertussis: should we vaccinate post transplant? Bone Marrow Transplant. 2006;37:793–4.PubMedCrossRefGoogle Scholar
  71. 71.
    Papadopoulos E, Young J, Kernan N, Boulad F, Castro-Malaspina H, O’Reilly R, et al. Use of the tetanus toxoid, reduced dose diphtheria and pertussis vaccine (Tdap) in allogeneic transplant (alloHCT) recipients. Blood. 2008;112(11):2214.Google Scholar
  72. 72.
    Parkkali T, Kayhty H, Lehtonen H, Ruutu T, Volin L, Eskola J, et al. Tetravalent meningococcal polysaccharide vaccine is immunogenic in adult allogeneic BMT recipients. Bone Marrow Transplant. 2001;27(1):79–84.PubMedCrossRefGoogle Scholar
  73. 73.
    Mahler MB, Taur Y, Jean R, Kernan NA, Prockop SE, Small TN. Safety and immunogenicity of the tetravalent protein-conjugated meningococcal vaccine (MCV4) in recipients of related and unrelated allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012;18(1):145–9. Epub 2011/08/09.PubMedCrossRefGoogle Scholar
  74. 74.
    Gahr P, DeVries AS, Wallace G, Miller C, Kenyon C, Sweet K, et al. An outbreak of measles in an undervaccinated community. Pediatrics. 2014;134(1):e220–8. Epub 2014/06/11.PubMedCrossRefGoogle Scholar
  75. 75.
    Colzani E, McDonald SA, Carrillo-Santisteve P, Busana MC, Lopalco P, Cassini A. Impact of measles national vaccination coverage on burden of measles across 29 Member States of the European Union and European Economic Area, 2006–2011. Vaccine. 2014;32(16):1814–9. Epub 2014/02/18.PubMedCrossRefGoogle Scholar
  76. 76.
    Nakano T, Shimono Y, Sugiyama K, Nishihara H, Higashigawa M, Komada Y, et al. Clinical features of measles in immunocompromised children. Acta Paediatr Jpn. 1996;38(3):212–7.PubMedCrossRefGoogle Scholar
  77. 77.
    Kaplan L, Daum R, Smaron M, McCarthy C. Severe measles in immunocompromised patients. JAMA. 1992;267(9):1237–41.PubMedCrossRefGoogle Scholar
  78. 78.
    Ljungman P, Fridell E, Lönnqvist B, Bolme P, Böttiger M, Gahrton G, et al. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine. J Infect Dis. 1989;159(4):610–5.PubMedCrossRefGoogle Scholar
  79. 79.
    Machado C, Sumita L, da Rocha I, Pannuti C, de Souza V. Early measles vaccination in bone marrow transplant recipients. Int J Infect Dis. 2002;6 Suppl 2:S38.CrossRefGoogle Scholar
  80. 80.
    Spoulou V, Giannaki M, Vounatsou M, Bakoula C, Grafakos S. Long-term immunity to measles, mumps and rubella after MMR vaccination among children with bone marrow transplants. Bone Marrow Transplant. 2004;33(12):1187–90. Epub 2004/04/13.PubMedCrossRefGoogle Scholar
  81. 81.
    King SM, Saunders EF, Petric M, Gold R. Response to measles, mumps and rubella vaccine in paediatric bone marrow transplant recipients. Bone Marrow Transplant. 1996;17(4):633–6.PubMedGoogle Scholar
  82. 82.
    Machado CM, de Souza V, Sumita LM, da Rocha I, Dulley FL, Pannuti CS. Early measles vaccination in bone marrow transplant recipients. Bone Marrow Transplant. 2005;35(8):787–91.PubMedCrossRefGoogle Scholar
  83. 83.
    Ljungman P, Engelhard D, de la Camara R, Einsele H, Locasciulli A, Martino R, et al. Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant. 2005;35(8):737–46.PubMedCrossRefGoogle Scholar
  84. 84.
    Sauerbrei A, Prager J, Hengst U, Zintl F, Wutzler P. Varicella vaccination in children after bone marrow transplantation. Bone Marrow Transplant. 1997;20:381–3.PubMedCrossRefGoogle Scholar
  85. 85.
    Chou JF, Kernan NA, Prockop S, Heller G, Scaradavou A, Kobos R, et al. Safety and immunogenicity of the live attenuated varicella vaccine following T replete or T cell-depleted related and unrelated allogeneic hematopoietic cell transplantation (alloHCT). Biol Blood Marrow Transplant. 2011;17(11):1708–13. Epub 2011/06/15.PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Kussmaul SC, Horn BN, Dvorak CC, Abramovitz L, Cowan MJ, Weintrub PS. Safety of the live, attenuated varicella vaccine in pediatric recipients of hematopoietic SCTs. Bone Marrow Transplant. 2010;45(11):1602–6. Epub 2010/03/02.PubMedCrossRefGoogle Scholar
  87. 87.
    Redman R, Nader S, Zerboni L, Liu C, Wong R, Brown B, et al. Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine. J Infect Dis. 1997;178:578–85.CrossRefGoogle Scholar
  88. 88.
    Issa NC, Marty FM, Leblebjian H, Galar A, Shea MM, Antin JH, et al. Live attenuated varicella-zoster vaccine in hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2014;20(2):285–7. Epub 2013/11/26.PubMedCrossRefGoogle Scholar
  89. 89.
    Mullane KM, Winston DJ, Wertheim MS, Betts RF, Poretz DM, Camacho LH, et al. Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adults. J Infect Dis. 2013;208(9):1375–85. Epub 2013/08/03.PubMedCrossRefGoogle Scholar
  90. 90.
    Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015. Epub 2015/04/29.Google Scholar
  91. 91.
    Erard V, Guthrie KA, Varley C, Heugel J, Wald A, Flowers ME, et al. One-year acyclovir prophylaxis for preventing varicella-zoster virus (VZV) disease following hematopoietic cell transplantation: no evidence of rebound VZV disease after drug discontinuation. Blood. 2007;110:3071–7.PubMedCrossRefGoogle Scholar
  92. 92.
    Rio B, Marjanovic Z, Lévy V, Hunault M, Bazarbachi A, Zittoun R. Vaccination for yellow fever after bone marrow transplantation. Bone Marrow Transplant. 1996;17 Suppl 1:95.Google Scholar
  93. 93.
    Nordoy T, Kolstad A, Endresen P, Holte H, Kvaloy S, Kvalheim G, et al. Persistent changes in the immune system 4–10 years after ABMT. Bone Marrow Transplant. 1999;24(8):873–8.PubMedCrossRefGoogle Scholar
  94. 94.
    Pauksen K, Duraj V, Ljungman P, Sjölin J, Öberg G, Lönnerholm G, et al. Immunity to and immunization against measles, rubella and mumps in patients after autologous bone marrow transplantation. Bone Marrow Transplant. 1992;9(6):427–32.PubMedGoogle Scholar
  95. 95.
    Pauksen K, Hammarström V, Ljungman P, Sjölin J, Öberg G, Lönnerholm G, et al. Immunity to poliovirus and immunization with inactivated poliovaccine after autologous bone marrow transplantation. Clin Infect Dis. 1994;18:547–52.PubMedCrossRefGoogle Scholar
  96. 96.
    Hammarström V, Pauksen K, Björkstrand B, Simonsson B, Öberg G, Ljungman P. Tetanus immunity in autologus bone marrow and blood stem cell transplant patients. Bone Marrow Transplant. 1998;22:67–72.PubMedCrossRefGoogle Scholar
  97. 97.
    Nordoy T, Husebekk A, Aaberge IS, Jenum PA, Samdal HH, Flugsrud LB, et al. Humoral immunity to viral and bacterial antigens in lymphoma patients 4–10 years after high-dose therapy with ABMT. Serological responses to revaccinations according to EBMT guidelines. Bone Marrow Transplant. 2001;28(7):681–7. Epub 2001/11/13.PubMedCrossRefGoogle Scholar
  98. 98.
    Nagler A, Ilan Y, Adler R, Or R, Naparstek E, Shouval D, et al. Successful immunization of autologous bone marrow transplantation recipients against hepatitis B virus by active vaccination. Bone Marrow Transplant. 1995;15:475–8.PubMedGoogle Scholar
  99. 99.
    Molrine D, Guinan E, Antin J, Wheeler C, Parsons S, Weinstein H, et al. Haemophilus influenzae type b (HIB)-conjugate immunization before bone marrow harvest in autologous bone marrow transplantation. Bone Marrow Transplant. 1996;17:1149–55.PubMedGoogle Scholar
  100. 100.
    Yri OE, Torfoss D, Hungnes O, Tierens A, Waalen K, Nordoy T, et al. Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. Blood. 2011;118(26):6769–71. Epub 2011/11/08.PubMedCrossRefGoogle Scholar
  101. 101.
    Bedognetti D, Zoppoli G, Massucco C, Zanardi E, Zupo S, Bruzzone A, et al. Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin’s lymphoma patients treated with rituximab-containing regimens. J Immunol. 2011;186(10):6044–55. Epub 2011/04/19.PubMedPubMedCentralCrossRefGoogle Scholar
  102. 102.
    Ljungman P, Nahi H, Linde A. Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study. Br J Haematol. 2005;130(1):96–8. Epub 2005/06/29.PubMedCrossRefGoogle Scholar
  103. 103.
    Gandhi MK, Egner W, Sizer L, Inman I, Zambon M, Craig JI, et al. Antibody responses to vaccinations given within the first two years after transplant are similar between autologous peripheral blood stem cell and bone marrow transplant recipients. Bone Marrow Transplant. 2001;28(8):775–81.PubMedCrossRefGoogle Scholar
  104. 104.
    Antin JH, Guinan EC, Avigan D, Soiffer RJ, Joyce RM, Martin VJ, et al. Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11(3):213–22. Epub 2005/03/04.PubMedCrossRefGoogle Scholar
  105. 105.
    Hammarström V, Pauksen K, Käyhtu H, Ljungman P. Antibody responses after vaccination with pneumococcal conjugate and polysaccharide vaccine in BMT recipients with chronic GVHD. 1999.Google Scholar
  106. 106.
    Small TN, Zelenetz AD, Noy A, Rice RD, Trippett TM, Abrey L, et al. Pertussis immunity and response to tetanus-reduced diphtheria-reduced pertussis vaccine (Tdap) after autologous peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2009;15(12):1538–42. Epub 2009/11/10.PubMedCrossRefGoogle Scholar
  107. 107.
    Sasadeusz J, Prince HM, Schwarer A, Szer J, Stork A, Bock HL, et al. Immunogenicity and safety of a two-dose live attenuated varicella vaccine given to adults following autologous hematopoietic stem cell transplantation. Transpl Infect Dis. 2014;16(6):1024–31. Epub 2014/10/02.PubMedCrossRefGoogle Scholar
  108. 108.
    Bhalla P, Forrest GN, Gershon M, Zhou Y, Chen J, LaRussa P, et al. Disseminated, persistent, and fatal infection due to the vaccine strain of varicella-zoster virus in an adult following stem cell transplantation. Clin Infect Dis. 2015;60(7):1068–74. Epub 2014/12/03.PubMedGoogle Scholar
  109. 109.
    Hata A, Asanuma H, Rinki M, Sharp M, Wong RM, Blume K, et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med. 2002;347(1):26–34.PubMedCrossRefGoogle Scholar
  110. 110.
    Stadtmauer EA, Sullivan KM, Marty FM, Dadwal SS, Papanicolaou GA, Shea TC, et al. A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. Blood. 2014;124(19):2921–9. Epub 2014/09/23.PubMedPubMedCentralCrossRefGoogle Scholar
  111. 111.
    Crosnier J, Junges P, Courouce A-M, et al. Randomized placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units II Haemodialysis patients. Lancet. 1981;2:797–800.CrossRefGoogle Scholar
  112. 112.
    Stevens C, Alter H, Taylor P, et al. Hepatitis B virus vaccine in patients receiving hemodialysis: immunogenecity and efficacy. N Engl J Med. 1984;311:496–501.PubMedCrossRefGoogle Scholar
  113. 113.
    Van Thiel D, el-Ashmawy L, Love K, Gaaler J, Starzl T. Response to hepatitis B vaccination by liver transplant candidates. Dig Dis Sci. 1992;37:1245–9.Google Scholar
  114. 114.
    Villeneuve E, Vincelette J, Villeneuve JP. Ineffectiveness of hepatitis B vaccination in cirrhotic patients waiting for liver transplantation. Can J Gastroenterol. 2000;14(Suppl B):59B–62B.Google Scholar
  115. 115.
    Sokal E, Ulla L, Otte J. Hepatitis B vaccine response before and after transplantation in 55 extrahepatic biliary atresia children. Dig Dis Sci. 1992;37:1250–2.PubMedCrossRefGoogle Scholar
  116. 116.
    Arslan M, Wiesner RH, Sievers C, Egan K, Zein NN. Double-dose accelerated hepatitis B vaccine in patients with end-stage liver disease. Liver Transpl. 2001;7(4):314–20.PubMedCrossRefGoogle Scholar
  117. 117.
    Horlander JC, Boyle N, Manam R, Schenk M, Herring S, Kwo PY, et al. Vaccination against hepatitis B in patients with chronic liver disease awaiting liver transplantation. Am J Med Sci. 1999;318(5):304–7.PubMedCrossRefGoogle Scholar
  118. 118.
    Dominguez M, Barcena R, Garcia M, Lopez-Sanroman A, Nuno J. Vaccination against hepatitis B virus in cirrhotic patients on liver transplant waiting list. Liver Transpl. 2000;6(4):440–2.PubMedCrossRefGoogle Scholar
  119. 119.
    Engler SH, Sauer PW, Golling M, Klar EA, Benz C, Stremmel W, et al. Immunogenicity of two accelerated hepatitis B vaccination protocols in liver transplant candidates. Eur J Gastroenterol Hepatol. 2001;13(4):363–7.PubMedCrossRefGoogle Scholar
  120. 120.
    Avery RK, Ljungman P. Prophylactic measures in the solid-organ recipient before transplantation. Clin Infect Dis. 2001;33 Suppl 1:S15–21.PubMedCrossRefGoogle Scholar
  121. 121.
    Lin CC, Chen CL, Concejero A, Wang CC, Wang SH, Liu YW, et al. Active immunization to prevent de novo hepatitis B virus infection in pediatric live donor liver recipients. Am J Transplant. 2007;7(1):195–200.PubMedCrossRefGoogle Scholar
  122. 122.
    Carey W, Pimentel R, Westweer M, et al. Failure of hepatitis B immunization in liver transplant patients: results of a prospective trial. Am J Gastroenterol. 1990;85:1590–2.PubMedGoogle Scholar
  123. 123.
    Dumot JA, Barnes DS, Younossi Z, Gordon SM, Avery RK, Domen RE, et al. Immunogenicity of hepatitis A vaccine in decompensated liver disease. Am J Gastroenterol. 1999;94(6):1601–4. Epub 1999/06/11.PubMedCrossRefGoogle Scholar
  124. 124.
    Broyer M, Boudailliez B. Varicella vaccine in children with chronic renal insufficiency. Postgrad Med J. 1985;61 Suppl 4:103–6.PubMedGoogle Scholar
  125. 125.
    Broyer M, Tete M, Guest G, Gagnadoux M. C R. Varicella and zoster in children after kidney transplantation: long-term results of vaccination. Pediatrics. 1997;99:35–9.PubMedCrossRefGoogle Scholar
  126. 126.
    Nithichaiyo C, Chongsrisawat V, Hutagalung Y, Bock HL, Poovorawa Y. Immunogenicity and adverse effects of live attenuated varicella vaccine (Oka-strain) in children with chronic liver disease. Asian Pac J Allergy Immunol. 2001;19(2):101–5.PubMedGoogle Scholar
  127. 127.
    Kruger S, Muller-Steinhardt M, Kirchner H, Kreft B. A 5-year follow-up on antibody response after diphtheria and tetanus vaccination in hemodialysis patients. Am J Kidney Dis. 2001;38(6):1264–70.PubMedCrossRefGoogle Scholar
  128. 128.
    Linnemann CJ, First M, Schiffman G. Response to pneumococcal vaccine in renal transplant and hemodialysis patients. Arch Intern Med. 1981;141:1637–40.PubMedCrossRefGoogle Scholar
  129. 129.
    Furth S, Neu A, Case B, Lederman H, Steinhoff M, Fivush B. Pneumococcal polysaccharide vaccine in children with chronic renal disease: a prospective study of antibody response and duration. J Pediatr. 1996;128:99–101.PubMedCrossRefGoogle Scholar
  130. 130.
    Campbell AL, Herold BC. Immunization of pediatric solid-organ transplantation candidates: immunizations in transplant candidates. Pediatr Transplant. 2005;9(5):652–61.PubMedCrossRefGoogle Scholar
  131. 131.
    Flynn JT, Frisch K, Kershaw DB, Sedman AB, Bunchman TE. Response to early measles-mumps-rubella vaccination in infants with chronic renal failure and/or receiving peritoneal dialysis. Adv Perit Dial. 1999;15:269–72.PubMedGoogle Scholar
  132. 132.
    Wagner D, Wagenbreth I, Stachan-Kunstyr R, Flik J. Failure of vaccination against hepatitis B with Gen H-B-Vax-D in immunosuppressed heart transplant patients. J Infect Dis. 1992;166:1021–8.CrossRefGoogle Scholar
  133. 133.
    Wagner D, Wagenbroth J, Stachan-Kunstyr R, Thoma H, Hammerling A, Flik J. Hepatitis B vaccination of immunosuppressed heart transplant recipients with the vaccine Hepa Gene 3 containing pre-S1, pre-S2, and S gene products. Clin Investig. 1994;72:240–352.Google Scholar
  134. 134.
    Duca P, Del Pont JM, D’Agostino D. Successful immune response to a recombinant hepatitis B vaccine in children after liver transplantation. J Pediatr Gastroenterol Nutr. 2001;32(2):168–70.PubMedCrossRefGoogle Scholar
  135. 135.
    Sanchez-Fueyo A, Rimola A, Grande L, Costa J, Mas A, Navasa M, et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: a new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology. 2000;31(2):496–501.PubMedCrossRefGoogle Scholar
  136. 136.
    Angelico M, Di Paolo D, Trinito MO, Petrolati A, Araco A, Zazza S, et al. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology. 2002;35(1):176–81.PubMedCrossRefGoogle Scholar
  137. 137.
    Starkel P, Stoffel M, Lerut J, Horsmans Y. Response to an experimental HBV vaccine permits withdrawal of HBIg prophylaxis in fulminant and selected chronic HBV-infected liver graft recipients. Liver Transpl. 2005;11(10):1228–34. Epub 2005/09/27.PubMedCrossRefGoogle Scholar
  138. 138.
    Bienzle U, Gunther M, Neuhaus R, Vandepapeliere P, Vollmar J, Lun A, et al. Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology. 2003;38(4):811–9. Epub 2003/09/27.PubMedGoogle Scholar
  139. 139.
    Gunther M, Neuhaus R, Bauer T, Jilg W, Holtz JA, Bienzle U. Immunization with an adjuvant hepatitis B vaccine in liver transplant recipients: antibody decline and booster vaccination with conventional vaccine. Liver Transpl. 2006;12(2):316–9. Epub 2006/02/01.PubMedCrossRefGoogle Scholar
  140. 140.
    Arslan M, Wiesner RH, Poterucha JJ, Zein NN. Safety and efficacy of hepatitis A vaccination in liver transplantation recipients. Transplantation. 2001;72(2):272–6.PubMedCrossRefGoogle Scholar
  141. 141.
    Gunther M, Stark K, Neuhaus R, Reinke P, Schroder K, Bienzle U. Rapid decline of antibodies after hepatitis A immunization in liver and renal transplant recipients. Transplantation. 2001;71(3):477–9.PubMedCrossRefGoogle Scholar
  142. 142.
    Jeon HJ, Ro H, Jeong JC, Koo TY, Han M, Min SI, et al. Efficacy and safety of hepatitis A vaccination in kidney transplant recipients. Transpl Infect Dis. 2014;16(3):511–5. Epub 2014/04/23.PubMedCrossRefGoogle Scholar
  143. 143.
    Kumar D, Michaels MG, Morris MI, Green M, Avery RK, Liu C, et al. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis. 2010;10(8):521–6. Epub 2010/07/14.PubMedPubMedCentralCrossRefGoogle Scholar
  144. 144.
    Sanchez-Fructuoso AI, Prats D, Naranjo P, Fernandez-Perez C, Gonzalez MJ, Mariano A, et al. Influenza virus immunization effectivity in kidney transplant patients subjected to two different triple-drug therapy immunosuppression protocols: mycophenolate versus azathioprine. Transplantation. 2000;69(3):436–9.PubMedCrossRefGoogle Scholar
  145. 145.
    Versluis D, Beyer W, Masurel N, Wenting G, Weimar W. Impairment of the immune response to influenza vaccination in renal transplant recipients by cyclosporine, but not azathioprine. Transplantation. 1986;42:376–9.PubMedCrossRefGoogle Scholar
  146. 146.
    Duchini A, Hendry RM, Nyberg LM, Viernes ME, Pockros PJ. Immune response to influenza vaccine in adult liver transplant recipients. Liver Transpl. 2001;7(4):311–3. Epub 2001/04/17.PubMedCrossRefGoogle Scholar
  147. 147.
    Soesman NM, Rimmelzwaan GF, Nieuwkoop NJ, Beyer WE, Tilanus HW, Kemmeren MH, et al. Efficacy of influenza vaccination in adult liver transplant recipients. J Med Virol. 2000;61(1):85–93.PubMedCrossRefGoogle Scholar
  148. 148.
    Dengler TJ, Strnad N, Buhring I, Zimmermann R, Girgsdies O, Kubler WE, et al. Differential immune response to influenza and pneumococcal vaccination in immunosuppressed patients after heart transplantation. Transplantation. 1998;66(10):1340–7.PubMedCrossRefGoogle Scholar
  149. 149.
    Fraund S, Wagner D, Pethig K, Drescher J, Girgsdies OE, Haverich A. Influenza vaccination in heart transplant recipients. J Heart Lung Transplant. 1999;18(3):220–5.PubMedCrossRefGoogle Scholar
  150. 150.
    Edvardsson VO, Flynn JT, Deforest A, Kaiser BA, Schulman SL, Bradley A, et al. Effective immunization against influenza in pediatric renal transplant recipients. Clin Transplant. 1996;10(6 Pt 1):556–60.PubMedGoogle Scholar
  151. 151.
    Furth S, Neu A, McColley S, Case B, Steinhoff M, Fivush B. Immune response to influenza vaccination in children with renal disease. Pediatr Nephrol. 1995;9:566–8.PubMedCrossRefGoogle Scholar
  152. 152.
    Mauch TJ, Bratton S, Myers T, Krane E, Gentry SR, Kashtan CE. Influenza B virus infection in pediatric solid organ transplant recipients. Pediatrics. 1994;94(2 Pt 1):225–9.PubMedGoogle Scholar
  153. 153.
    Madan RP, Tan M, Fernandez-Sesma A, Moran TM, Emre S, Campbell A, et al. A prospective, comparative study of the immune response to inactivated influenza vaccine in pediatric liver transplant recipients and their healthy siblings. Clin Infect Dis. 2008;46(5):712–8. Epub 2008/01/31.PubMedPubMedCentralCrossRefGoogle Scholar
  154. 154.
    Hayney MS, Welter DL, Francois M, Reynolds AM, Love RB. Influenza vaccine antibody responses in lung transplant recipients. Prog Transplant. 2004;14(4):346–51.PubMedCrossRefGoogle Scholar
  155. 155.
    Morelon E, Noble CP, Daoud S, Cahen R, Goujon-Henry C, Weber F, et al. Immunogenicity and safety of intradermal influenza vaccination in renal transplant patients who were non-responders to conventional influenza vaccination. Vaccine. 2010;28(42):6885–90. Epub 2010/08/17.PubMedCrossRefGoogle Scholar
  156. 156.
    Baluch A, Humar A, Eurich D, Egli A, Liacini A, Hoschler K, et al. Randomized controlled trial of high-dose intradermal versus standard-dose intramuscular influenza vaccine in organ transplant recipients. Am J Transplant. 2013;13(4):1026–33. Epub 2013/02/15.PubMedCrossRefGoogle Scholar
  157. 157.
    Beck CR, McKenzie BC, Hashim AB, Harris RC, University of Nottingham Influenza and the ImmunoCompromised (UNIIC) Study Group, et al. Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by etiology. J Infect Dis. 2012;206(8):1250–9. Epub 2012/08/21.PubMedCrossRefGoogle Scholar
  158. 158.
    Eckerle I, Rosenberger KD, Zwahlen M, Junghanss T. Serologic vaccination response after solid organ transplantation: a systematic review. PLoS One. 2013;8(2), e56974. Epub 2013/03/02.PubMedPubMedCentralCrossRefGoogle Scholar
  159. 159.
    Magnani G, Falchetti E, Pollini G, Reggiani LB, Grigioni F, Coccolo F, et al. Safety and efficacy of two types of influenza vaccination in heart transplant recipients: a prospective randomised controlled study. J Heart Lung Transplant. 2005;24(5):588–92.PubMedCrossRefGoogle Scholar
  160. 160.
    Lawal A, Basler C, Branch A, Gutierrez J, Schwartz M, Schiano TD. Influenza vaccination in orthotopic liver transplant recipients: absence of post administration ALT elevation. Am J Transplant. 2004;4(11):1805–9. Epub 2004/10/13.PubMedCrossRefGoogle Scholar
  161. 161.
    Versluis DJ, Beyer WE, Masurel N, Wenting GJ, Weimar W. Impairment of the immune response to influenza vaccination in renal transplant recipients by cyclosporine, but not azathioprine. Transplantation. 1986;42(4):376–9. Epub 1986/10/01.PubMedCrossRefGoogle Scholar
  162. 162.
    Kimball P, Verbeke S, Flattery M, Rhodes C, Tolman D. Influenza vaccination does not promote cellular or humoral activation among heart transplant recipients. Transplantation. 2000;69(11):2449–51.PubMedCrossRefGoogle Scholar
  163. 163.
    Burbach G, Bienzle U, Stark K, Rayes N, Neuhaus R, Serke S, et al. Influenza vaccination in liver transplant recipients. Transplantation. 1999;67(5):753–5.PubMedCrossRefGoogle Scholar
  164. 164.
    Hurst FP, Lee JJ, Jindal RM, Agodoa LY, Abbott KC. Outcomes associated with influenza vaccination in the first year after kidney transplantation. Clin J Am Soc Nephrol. 2011;6(5):1192–7. Epub 2011/04/23.PubMedPubMedCentralCrossRefGoogle Scholar
  165. 165.
    Danzinger-Isakov L, Kumar D. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant. 2009;9 Suppl 4:S258–62. Epub 2010/01/28.PubMedCrossRefGoogle Scholar
  166. 166.
    Sever MS, Yildiz A, Eraksoy H, Badur S, Yuksel-Onel D, Gorcin B, et al. Immune response to Haemophilus influenzae type B vaccination in renal transplant recipients with well-functioning allografts. Nephron. 1999;81(1):55–9.PubMedCrossRefGoogle Scholar
  167. 167.
    Dengler T, Strnad N, Zimmermann R, Allers C, Markus B, Nessen S, et al. Pneumococcal vaccination after heart and liver transplantation. Immune responses in immunosuppressed patients and in healthy controls. Dtsch Med Wochenschr. 1996;121:1519–25.PubMedCrossRefGoogle Scholar
  168. 168.
    Kazancioglu R, Sever MS, Yuksel-Onel D, Eraksoy H, Yildiz A, Celik AV, et al. Immunization of renal transplant recipients with pneumococcal polysaccharide vaccine. Clin Transplant. 2000;14(1):61–5.PubMedCrossRefGoogle Scholar
  169. 169.
    Blumberg EA, Brozena SC, Stutman P, Wood D, Phan HM, Musher DM. Immunogenicity of pneumococcal vaccine in heart transplant recipients. Clin Infect Dis. 2001;32(2):307–10.PubMedCrossRefGoogle Scholar
  170. 170.
    McCashland TM, Preheim LC, Gentry MJ. Pneumococcal vaccine response in cirrhosis and liver transplantation. J Infect Dis. 2000;181(2):757–60.PubMedCrossRefGoogle Scholar
  171. 171.
    Kumar D, Rotstein C, Miyata G, Arlen D, Humar A. Randomized, double-blind, controlled trial of pneumococcal vaccination in renal transplant recipients. J Infect Dis. 2003;187(10):1639–45.PubMedCrossRefGoogle Scholar
  172. 172.
    Kumar D, Welsh B, Siegal D, Chen MH, Humar A. Immunogenicity of pneumococcal vaccine in renal transplant recipients—three year follow-up of a randomized trial. Am J Transplant. 2007;7(3):633–8. Epub 2007/01/16.PubMedCrossRefGoogle Scholar
  173. 173.
    Kumar D, Chen MH, Wong G, Cobos I, Welsh B, Siegal D, et al. A randomized, double-blind, placebo-controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in adult liver transplant recipients. Clin Infect Dis. 2008;47(7):885–92.PubMedCrossRefGoogle Scholar
  174. 174.
    Enke BU, Bokenkamp A, Offner G, Bartmann P, Brodehl J. Response to diphtheria and tetanus booster vaccination in pediatric renal transplant recipients. Transplantation. 1997;64(2):237–41.PubMedCrossRefGoogle Scholar
  175. 175.
    Gomez-Lobo V, Whyte T, Kaufman S, Torres C, Moudgil A. Immunogenicity of a prophylactic quadrivalent human papillomavirus L1 virus-like particle vaccine in male and female adolescent transplant recipients. Pediatr Transplant. 2014;18(3):310–5. Epub 2014/02/04.PubMedCrossRefGoogle Scholar
  176. 176.
    Griffiths PD, Stanton A, McCarrell E, Smith C, Osman M, Harber M, et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet. 2011;377(9773):1256–63. Epub 2011/04/13.PubMedPubMedCentralCrossRefGoogle Scholar
  177. 177.
    Dengler TJ, Zimmermann R, Meyer J, Sack FU, Girgsdies O, Kubler WE. Vaccination against tick-borne encephalitis under therapeutic immunosuppression. Reduced efficacy in heart transplant recipients. Vaccine. 1999;17(7–8):867–74.PubMedCrossRefGoogle Scholar
  178. 178.
    Zamora I, Simon J, Da Silva M, Piqueras A. Attenuated varicella virus vaccine in children with renal transplants. Pediatr Nephrol. 1994;8:190–2.PubMedCrossRefGoogle Scholar
  179. 179.
    Weinberg A, Horslen SP, Kaufman SS, Jesser R, Devoll-Zabrocki A, Fleckten BL, et al. Safety and immunogenicity of varicella-zoster virus vaccine in pediatric liver and intestine transplant recipients. Am J Transplant. 2006;6(3):565–8.PubMedCrossRefGoogle Scholar
  180. 180.
    Khan S, Erlichman J, Rand EB. Live virus immunization after orthotopic liver transplantation. Pediatr Transplant. 2006;10(1):78–82.PubMedCrossRefGoogle Scholar
  181. 181.
    Levitsky J, Te HS, Faust TW, Cohen SM. Varicella infection following varicella vaccination in a liver transplant recipient. Am J Transplant. 2002;2(9):880–2. Epub 2002/10/24.PubMedCrossRefGoogle Scholar
  182. 182.
    Kraft JN, Shaw JC. Varicella infection caused by Oka strain vaccine in a heart transplant recipient. Arch Dermatol. 2006;142(7):943–5. Epub 2006/07/19.PubMedCrossRefGoogle Scholar
  183. 183.
    Rand E, McCarthy C, Whitington P. Measles vaccination after orthoptic liver transplantation. J Pediatr. 1993;123:87–9.PubMedCrossRefGoogle Scholar
  184. 184.
    Turner A, Jeyaratnam D, Haworth F, Sinha MD, Hughes E, Cohen B, et al. Measles-associated encephalopathy in children with renal transplants. Am J Transplant. 2006;6(6):1459–65.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Department of HematologyKarolinska University HospitalStockholmSweden

Personalised recommendations